|
1
|
Crystal RG, Bitterman PB, Rennard SI,
Hance AJ and Keogh BA: Interstitial lung diseases of unknown cause.
Disorders characterized by chronic inflammation of the lower
respiratory tract (first of two parts). N Engl J Med. 310:154–166.
1984.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kondoh Y, Taniguchi H, Kawabata Y, Yokoi
T, Suzuki K and Takagi K: Acute exacerbation in idiopathic
pulmonary fibrosis. Analysis of clinical and pathologic findings in
three cases. Chest. 103:1808–1812. 1993.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Song JW, Hong S-B, Lim C-M, Koh Y and Kim
DS: Acute exacerbation of idiopathic pulmonary fibrosis: Incidence,
risk factors and outcome. Eur Respir J. 37:356–363. 2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Agarwal R and Jindal SK: Acute
exacerbation of idiopathic pulmonary fibrosis: A systematic review.
Eur J Intern Med. 19:227–235. 2008.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Imokawa S, Sato A, Hayakawa H, Kotani M,
Urano T and Takada A: Tissue factor expression and fibrin
deposition in the lungs of patients with idiopathic pulmonary
fibrosis and systemic sclerosis. Am J Respir Crit Care Med.
156:631–636. 1997.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kotani I, Sato A, Hayakawa H, Urano T,
Takada Y and Takada A: Increased procoagulant and antifibrinolytic
activities in the lungs with idiopathic pulmonary fibrosis. Thromb
Res. 77:493–504. 1995.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kubo H, Nakayama K, Yanai M, Suzuki T,
Yamaya M, Watanabe M and Sasaki H: Anticoagulant therapy for
idiopathic pulmonary fibrosis. Chest. 128:1475–1482.
2005.PubMed/NCBI
|
|
8
|
Noth I, Anstrom KJ, Calvert SB, de Andrade
J, Flaherty KR, Glazer C, Kaner RJ and Olman MA: Idiopathic
Pulmonary Fibrosis Clinical Research Network (IPFnet): A
placebo-controlled randomized trial of warfarin in idiopathic
pulmonary fibrosis. Am J Respir Crit Care Med. 186:88–95.
2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sakamoto S, Homma S, Miyamoto A, Kurosaki
A, Fujii T and Yoshimura K: Cyclosporin A in the treatment of acute
exacerbation of idiopathic pulmonary fibrosis. Intern Med.
49:109–115. 2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ryerson CJ, Cottin V, Brown KK and Collard
HR: Acute exacerbation of idiopathic pulmonary fibrosis: Shifting
the paradigm. Eur Respir J. 46:512–520. 2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ogawa Y, Yamakawa K, Ogura H, Kiguchi T,
Mohri T, Nakamori Y, Kuwagata Y, Shimazu T, Hamasaki T and Fujimi
S: Recombinant human soluble thrombomodulin improves mortality and
respiratory dysfunction in patients with severe sepsis. J Trauma
Acute Care Surg. 72:1150–1157. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ito T, Thachil J, Asakura H, Levy JH and
Iba T: Thrombomodulin in disseminated intravascular coagulation and
other critical conditions-a multi-faceted anticoagulant protein
with therapeutic potential. Crit Care. 23(280)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kataoka K, Taniguchi H, Kondoh Y,
Nishiyama O, Kimura T, Matsuda T, Yokoyama T, Sakamoto K and Ando
M: Recombinant human thrombomodulin in acute exacerbation of
idiopathic pulmonary fibrosis. Chest. 148:436–443. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hayakawa S, Matsuzawa Y, Irie T, Rikitake
H, Okada N and Suzuki Y: Efficacy of recombinant human soluble
thrombomodulin for the treatment of acute exacerbation of
idiopathic pulmonary fibrosis: A single arm, non-randomized
prospective clinical trial. Multidiscip Respir Med.
11(38)2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Tsushima K, Yamaguchi K, Kono Y, Yokoyama
T, Kubo K, Matsumura T, Ichimura Y, Abe M, Terada J and Tatsumi K:
Thrombomodulin for acute exacerbations of idiopathic pulmonary
fibrosis: A proof of concept study. Pulm Pharmacol Ther.
29:233–240. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Moher D, Liberati A, Tetzlaff J and Altman
DG: PRISMA Group: Preferred reporting items for systematic reviews
and meta-analyses: The PRISMA statement. PLoS Med.
6(e1000097)2009.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Higgins J, Thomas J, Chandler J, Cumpston
M, Li T, Page M and Welch V (eds): Cochrane handbook for systemic
reviews of interventions. 2nd edition. Cochrane, 2019. John Wiley
& Sons, Inc., Hoboken NJ. https://doi.org/10.1002/9781119536604.
|
|
18
|
Schardt C, Adams MB, Owens T, Keitz S and
Fontelo P: Utilization of the PICO framework to improve searching
PubMed for clinical questions. BMC Med Inform Decis Mak.
7(16)2007.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS,
Hahn S, Jang BH and Son HJ: Testing a tool for assessing the risk
of bias for nonrandomized studies showed moderate reliability and
promising validity. J Clin Epidemiol. 66:408–414. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Isshiki T, Sakamoto S, Kinoshita A, Sugino
K, Kurosaki A and Homma S: Recombinant human soluble thrombomodulin
treatment for acute exacerbation of idiopathic pulmonary fibrosis:
A retrospective study. Respiration. 89:201–207. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Shimizu H, Sakamoto S, Isshiki T, Furuya
K, Kurosaki A and Homma S: Association of serum high-mobility group
box protein 1 level with outcomes of acute exacerbation of
idiopathic pulmonary fibrosis and fibrosing nonspecific
interstitial pneumonia. PLoS One. 13(e0196558)2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Sakamoto S, Shimizu H, Isshiki T, Sugino
K, Kurosaki A and Homma S: Recombinant human soluble thrombomodulin
for acute exacerbation of idiopathic pulmonary fibrosis: A
historically controlled study. Respir Investig. 56:136–143.
2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Arai T, Kida H, Ogata Y, Marumo S,
Matsuoka H, Gohma I, Yamamoto S, Mori M, Sugimoto C, Tachibana K,
et al: Osaka Acute Exacerbation of Interstitial Pneumonia Research
Group: Recombinant thrombomodulin for acute exacerbation in
idiopathic interstitial pneumonias. Respirology. 24:658–666.
2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Abe M, Tsushima K, Matsumura T, Ishiwata
T, Ichimura Y, Ikari J, Terada J, Tada Y, Sakao S, Tanabe N, et al:
Efficacy of thrombomodulin for acute exacerbation of idiopathic
pulmonary fibrosis and nonspecific interstitial pneumonia: A
nonrandomized prospective study. Drug Des Devel Ther. 9:5755–5762.
2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Raghu G, Rochwerg B, Zhang Y, Garcia CA,
Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, et
al: American Thoracic Society; European Respiratory society;
Japanese Respiratory Society; Latin American Thoracic Association:
An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment
of idiopathic pulmonary fibrosis. An update of the 2011 clinical
practice guideline. Am J Respir Crit Care Med. 192:3–19.
2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Horita N, Akahane M, Okada Y, Kobayashi Y,
Arai T, Amano I, Takezawa T, To M and To Y: Tacrolimus and steroid
treatment for acute exacerbation of idiopathic pulmonary fibrosis.
Intern Med. 50:189–195. 2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Cuerpo S, Moisés J, Hernández-González F,
Benegas M, Ramirez J, Sánchez M, Agustí À and Sellares J: Acute
exacerbations of idiopathic pulmonary fibrosis: Does clinical
stratification or steroid treatment matter? Chron Respir Dis.
16(1479973119869334)2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Collard HR, Calfee CS, Wolters PJ, Song
JW, Hong SB, Brady S, Ishizaka A, Jones KD, King TE Jr, Matthay MA,
et al: Plasma biomarker profiles in acute exacerbation of
idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol.
299:3–7. 2010.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Okamoto T, Tanigami H, Suzuki K and
Shimaoka M: Thrombomodulin: A bifunctional modulator of
inflammation and coagulation in sepsis. Crit Care Res Pract.
2012(614545)2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Hayakawa M, Kushimoto S, Watanabe E, Goto
K, Suzuki Y, Kotani T, Kiguchi T, Yatabe T, Tagawa J, Komatsu F, et
al: Pharmacokinetics of recombinant human soluble thrombomodulin in
disseminated intravascular coagulation patients with acute renal
dysfunction. Thromb Haemost. 117:851–859. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kamiya H and Panlaqui OM: The efficacy of
recombinant human soluble thrombomodulin (rhsTM) treatment for
acute exacerbation of idiopathic pulmonary fibrosis: A systematic
review and meta-analysis. BMC Pulm Med. 20(57)2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Eguchi Y, Gando S, Ishikura H, Saitoh D,
Mimuro J, Takahashi H, Kitajima I, Tsuji H, Matsushita T, Tsujita
R, et al: Post-marketing surveillance data of thrombomodulin alfa:
Sub-analysis in patients with sepsis-induced disseminated
intravascular coagulation. J Intensive Care. 2(30)2014.PubMed/NCBI View Article : Google Scholar
|
